Life Sciences Investor Forum

AI SummaryClose X

Coiled Therapeutics plc announced that its Chairman will present at the Life Sciences Investor Forum on June 25, 2026, providing an opportunity for investors to engage with management. The company, listed on AIM and OTCQB, is a clinical-stage oncology firm developing precision medicines, with its lead program AO-252, a TACC3 inhibitor, currently in Phase I trials for hard-to-treat cancers. The presentation will likely cover updates on the ongoing clinical trials and the company's strategic direction.

Disclaimer*

UK 100

Latest directors dealings